Singapore markets open in 4 hours 5 minutes

Hyphens Pharma International Limited (1J5.SI)

SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.3050+0.0100 (+3.39%)
At close: 04:10PM SGT

Hyphens Pharma International Limited

16 Tai Seng Street
Level 4
Singapore 534138
Singapore
65 6338 8551
https://www.hyphens.com.sg

Sector(s)Healthcare
IndustryPharmaceutical Retailers
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. See Wah LimExec. Chairman & CEON/AN/A1968
Ms. Lee Wei FangChief Financial OfficerN/AN/A1976
Mr. Yann Alain MarcheChief Operating OfficerN/AN/AN/A
Ms. Foong Jen TangAdmin. Mang.N/AN/AN/A
Mr. Chwee Choon TanExec. Director & Regional Director of IndochinaN/AN/A1957
Ms. Stella AngHead of Regulatory AffairsN/AN/AN/A
Ms. Loh ShaoliCountry Head of PhilippinesN/AN/AN/A
Mr. Jamal IflizarCountry Head of IndonesiaN/AN/AN/A
Mr. Ang FrancisCountry Head of MalaysiaN/AN/AN/A
Ms. Sher Mei Lim C.A.Company Sec.N/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.

Description

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, the Philippines, Indonesia, and Malaysia. The company's Specialty Pharma Principals segment sells and markets specialty pharmaceutical products, including Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup, Lidose, and Piascledine through distributorship or licensing, and supply agreements. This segment offers products in various therapeutic areas or medical specialties, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, and family medicine. Its Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. It offers dermocosmetic products under the Ceradan and TDF brands through medical professionals, such as general practitioners, dermatologists, pediatricians, and pharmacists; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand. The company's Medical Hypermart and Digital segment engages in the wholesale of pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. This segment also operates an online B2B platform. It also markets and distributes its products in Bangladesh, Brunei, Cambodia, China, Hong Kong, Macau, Myanmar, Oman, Sri Lanka, and South Korea. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. It was founded in 1998 and is headquartered in Singapore. Hyphens Pharma International Limited is a subsidiary of Inomed Holding Pte Ltd.

Corporate governance

Hyphens Pharma International Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.